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Abstract
Background: Oxytocin (10 IU) is the drug of choice for prevention of postpartum hemorrhage (PPH). Its use has generally
been restricted to medically trained staff in health facilities. We assessed the effectiveness, safety, and feasibility of PPH
prevention using oxytocin injected by peripheral health care providers without midwifery skills at home births.
Methods and Findings: This community-based, cluster-randomized trial was conducted in four rural districts in Ghana. We
randomly allocated 54 community health officers (stratified on district and catchment area distance to a health facility:
$10 km versus ,10 km) to intervention (one injection of oxytocin [10 IU] one minute after birth) and control (no provision
of prophylactic oxytocin) arms. Births attended by a community health officer constituted a cluster. Our primary outcome
was PPH, using multiple definitions; (PPH-1) blood loss $500 mL; (PPH-2) PPH-1 plus women who received early treatment
for PPH; and (PPH-3) PPH-2 plus any other women referred to hospital for postpartum bleeding. Unsafe practice is defined
as oxytocin use before delivery of the baby. We enrolled 689 and 897 women, respectively, into oxytocin and control arms
of the trial from April 2011 to November 2012. In oxytocin and control arms, respectively, PPH-1 rates were 2.6% versus 5.5%
(RR: 0.49; 95% CI: 0.27–0.88); PPH-2 rates were 3.8% versus 10.8% (RR: 0.35; 95% CI: 0.18–0.63), and PPH-3 rates were similar
to those of PPH-2. Compared to women in control clusters, those in the intervention clusters lost 45.1 mL (17.7–72.6) less
blood. There were no cases of oxytocin use before delivery of the baby and no major adverse events requiring notification
of the institutional review boards. Limitations include an unblinded trial and imbalanced numbers of participants, favoring
controls.
Conclusion: Maternal health care planners can consider adapting this model to extend the use of oxytocin into peripheral
settings including, in some contexts, home births.
Trial registration: ClinicalTrials.gov NCT01108289
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Introduction
Hemorrhage is the leading cause of maternal death in low-
income countries, estimated to be responsible for one-third of such
deaths annually [1]. Postpartum hemorrhage (PPH) is generally
accepted to represent the majority of hemorrhage cases and to be
predominantly caused by uterine atony. Maternal deaths from
hemorrhage in sub-Saharan Africa account for one in five of all
maternal deaths world-wide. In sub-Saharan African countries,
rates of home birth remain high (decreasing only slowly from 64%
in 1995 to 50% in 2008 [2–4]), and it is at home births where the
consequences of PPH are most severe given the need for
immediate treatment of PPH.
Consequently, prevention and treatment of PPH have been the
subject of a large body of research over the past decade, prompting
the World Health Organization (WHO) to issue a series of
evidence-informed guidelines for strategic program planning [5–
7]. The most recent WHO guideline on PPH prevention
recommends the use of a uterotonic drug without other
components of active management of the third stage of labor,
particularly where skilled birth attendants are not available. In
such settings, the use of intramuscular oxytocin (10 IU) via either
syringe or a compact, pre-filled, auto-disposable device by an
auxiliary nurse, or oral misoprostol (600 mcg) by either an
auxiliary nurse or lay health worker trained in the use of
misoprostol, is recommended [8]. To date, WHO continues to
recommend oxytocin as the drug of choice for PPH prevention at
home and in health facilities due to its effectiveness and lack of side
effects. Although other uterotonic drugs are listed as alternative
drugs, WHO guidelines state ‘‘that these alternative drugs should
not detract from the goal of widely accessible oxytocin’’ [7].
Results from a Cochrane meta-analysis of six trials in high-
income-country health facilities showed that prophylactic oxytocin
(using intramuscular and intravenous dosages from 3 to 10 IU) was
associated with a relative risk of 0?50 for PPH ($500 mL blood
loss; 95% CI: 0?43–0?59) and 0?61 for severe PPH ($1000 mL
blood loss; 95% CI: 0?44–0?87) relative to women receiving no
uterotonics during the third stage of labor [9].
Research supporting community-based PPH prevention in-
cludes three community-based randomized trials in India,
Pakistan, and Guinea Bissau that assessed the use of misoprostol
(600 mcg) and found protective effects of varying magnitude. PPH
was reduced by 47% in the rural India trial where auxiliary nurse
midwives attending births in rural health centers administered oral
600 mcg tablets of misoprostol versus placebo (RR: 0.53; 95% CI:
0.39–0.74) [10] and by 24% in rural Pakistan where traditional
birth attendants administered oral misoprostol (600 mcg) versus
placebo at home births (RR: 0.76; 95% CI 0.59–0.97) [11]. Hoj
and colleagues reported an 11% non-significant reduction in risk
of PPH for midwife-assisted births at a health center in Bissau,
Guinea Bissau (RR: 0.89; 95% CI: 0.76–1.04) [12]. The trials in
India and Guinea Bissau also found significant decreases in the risk
of severe PPH (blood loss $1000 mL); for example, the risk in
India was 0.20 (95% CI: 0.04–0.91) [10] and in Guinea Bissau the
risk was 0.66 (95% CI: 0.45–0.98) [12]. In all three trials,
misoprostol was significantly associated with side effects (shivering
and/or fever). To our knowledge, this is the first paper in the
literature to describe a randomized trial of prophylactic oxytocin
at home births.
The ongoing challenge is to determine the effectiveness and
safety of uterotonic drug options and to identify the contexts in
which their advantages can be exploited and their constraints
overcome. For example, there are three main concerns regarding
use of community-based prophylactic oxytocin by unskilled
attendants: (1) such providers are often not authorized nor trained
to administer injections; (2) potential administration of oxytocin
before delivery of the baby to speed labor, which when medically
non-indicated and/or when performed without adequate medical
supervision and infrastructure can be detrimental to the fetus and
the woman [13]; and (3) oxytocin is heat labile [14]. However, an
important characteristic of oxytocin is that there are no
contraindications for administering an additional 10 IU of
oxytocin as an early treatment in women experiencing PPH
following prophylaxis with oxytocin. The recommended practice
for PPH treatment in health facilities is—where available—
intravenous oxytocin, but intramuscular use is not contraindicated
as a first response before seeking a higher level of care [7]. In
contrast, a key advantage to misoprostol for PPH prophylaxis is
that it is heat stable (though requires appropriate manufacturer
packaging to avoid degradation from humidity), an important
advantage for peripheral settings with difficult access to a health
facility. However, given that half or more of PPH cases will
continue to occur where misoprostol is used prophylactically,
women’s only option for treatment is fundal massage and referral
since current concerns regarding toxicity prevent misoprostol
administration for PPH treatment to women who have received it
for prophylaxis [7]. Thus, the women in greatest need, those for
whom prophylaxis has been ineffective, must rely on referral and
transport from a peripheral site. This limitation is rarely discussed;
the India and Pakistan community-based prevention trials provide
limited information on successful referral and transport for women
experiencing PPH. Another point rarely discussed publicly is the
potential use of misoprostol as an abortifacient, which prevents its
inclusion in the national drug policies of some countries. Oxytocin
is a well-known medicine without this issue.
WHO and others have specifically called for research to
determine the safety of prophylactic oxytocin use with an unskilled
birth attendant at home births in low-income countries [7,8]. The
trial reported here is designed to assess the effectiveness of a mode
of service delivery; that is, can the evidence-based practice of using
oxytocin for PPH prevention be effectively delivered by a
peripheral health care cadre at home births? We aim to assess
whether this mode of service delivery can (a) achieve a health
benefit and (b) be delivered safely and (c) be feasible from a practical
standpoint. PPH is the primary outcome of this study for two
reasons: (1) there is general consensus regarding the outcome
($500 mLs of blood loss constitutes PPH) and (2) validated tools
exist for the measurement of blood loss in a home setting [15]. The
study is designed as a cluster-randomized trial in which all births
attended by a peripheral health care cadre constitute a cluster.
Methods
Ethics Statement
The study protocol was approved by the Kintampo Health
Research Center (KHRC) and the Ghana Health Service (GHS)
Ethical Review Committees, the Institutional Review Board of the
Johns Hopkins Bloomberg School of Public Health (#00002673),
and the Research Ethics Committee of PATH (#HS547). The
protocol is reviewed and reapproved annually.
Study Design and Participants
This community-based, cluster-randomized trial was designed
to determine if oxytocin (10 IU) by injection via Uniject by
community health officers (CHOs) at home-based births in four
rural districts in Ghana reduces the risk of PPH by 50% relative to
Oxytocin to Prevent Postpartum Hemorrhage in Ghana
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CHO-attended deliveries where prophylaxis was not provided.
Births attended by a CHO constitute a cluster. The random
allocation was done at the cluster level (i.e., CHOs) rather than at
the individual level (i.e., each delivering woman) so that each
individual CHO was given a constant set of responsibilities,
thereby simplifying the training and, most importantly, reducing
the likelihood of inadvertent cross-over. We have previously
published details on the design and implementation of this trial
[16]. Briefly, the trial was conducted in four predominantly rural
districts in Brong-Ahafo region. These are: Kintampo North,
Kintampo South, Nkoranza North, and Nkoranza South. The
maternal mortality ratio in that general area was 363 per 100,000
live births in 2008 [17]. The institutional birth rate in the study
districts before enrollment commenced was 64%. National data
from the Demographic and Health Surveys suggest that there is
negligible use of skilled birth attendants at home births in Ghana
[18]. Health facility delivery is free in Ghana. CHOs are
employees of the GHS, trained for two years to provide outreach
health services to the rural population, including childhood
immunization, antenatal and postnatal care, and family planning.
CHOs do not have midwifery skills. The majority of CHOs in this
trial were recent CHO training program graduates.
Initially, we identified the catchment areas of 52 CHOs within
study districts. KHRC field workers were responsible for the
identification of all pregnant women. At seven or more months’
gestation, field workers sought written initial informed consent for
the trial. Women agreeing to participate, should they choose to
deliver at home, were asked to contact the field worker after the
onset of labor. There were no exclusion criteria. When contacted
after onset of labor, the field worker telephoned the CHO and
both travelled to the woman’s household, where the written ‘‘final
consent’’ process was administered. Enrolled women are those
who provided final consent and whose delivery was observed by
the CHO. The CHOs did not in any way manage the delivery;
they (1) observed, (2) provided the intervention (according to
random allocation), (3) measured the outcomes, and (4) provided
early treatment for PPH and facilitated referral, when needed.
Randomization and Masking
The 52 CHOs were randomly allocated equally to either the
intervention (oxytocin) or the control group; this allocation was
stratified by both district and distance (#10 km or .10 km) to
emergency obstetric care. The randomization sequence was
determined using Stata (version 12). The random allocation
sequence was generated by LCM, while enrollment of the clusters
was done by SN and KHRC in collaboration with the GHS. Two
additional CHO catchment areas were selected to replace non-
compliant CHOs both of which were in the oxytocin group,
following the single interim meeting of the Data Safety and
Monitoring Board in December 2011. The new catchment areas
were adjacent to those of the non-compliant CHOs with similar
characteristics. The random allocation was not masked because
the efficacy of oxytocin is not in doubt, use of a placebo was
unacceptable to the GHS, and filling the Uniject device with saline
has prohibitive testing requirements.
Intervention
The intervention was delivered by CHOs in the oxytocin group.
The 28 CHOs allocated to this group administered an injection of
oxytocin (10 IU) in the thigh one minute following delivery using
an oxytocin in Uniject device, an auto-disposable syringe prefilled
with oxytocin (10 IU) (Figure 1). The injection-ready format
reduces wastage, simplifies logistics, and was designed for use both
by lay health personnel who do not normally administer injections
and in areas with limited health infrastructure. While the device
has been used for observational studies [19–22], this is the first
randomized trial using oxytocin in Uniject to evaluate impact on a
health outcome. Supply of oxytocin in Uniject was manufactured
by the Instituto Biolo´gico Argentino (BIOL) and imported into
Ghana for study purposes. A time/temperature indicator sticker
was adhered to the foil envelope containing the device. This
indicator is designed to change color with cumulative heat
exposure to indicate when the drug should be discarded.
The 26 control group CHOs did not provide this prophylactic
injection to women they observed. All other CHO activities
(outcome measurement, data collection, and early treatment and
referral when necessary, as described below) were identical across
the control and oxytocin CHOs. All CHOs were required to
successfully complete an allocation-specific, five-day competency-
based assessment and were trained to palpate the uterus for a twin
prior to administration of oxytocin. Oxytocin in Uniject supplies
were kept refrigerated at KHRC and distributed approximately
monthly in small quantities to CHOs, who stored them outside of
a temperature-controlled cold chain at their CHO compound.
CHOs requested additional supplies as needed from Field
Supervisors.
Response to Bleeding
CHOs in both groups were instructed to initiate emergency
transport from KHRC if a woman was actively bleeding at
400 mL blood loss. Women who (1) lost more than 500 mL blood
or (2) gushed blood and/or bled lime-sized blood clots received
early treatment with oxytocin in Uniject (10 IU) prior to transport
to one of four local hospitals. Emergency transport was also
available from KHRC for other maternal and newborn compli-
cations.
Outcome Measurement
CHOs in both groups measured postpartum blood loss by
folding a BRASSS-V calibrated plastic drape under the woman’s
back prior to delivery. The drape was unfolded immediately after
delivery so that the pouch could be used for blood collection. The
drape has been validated and used in a number of previous PPH
trials [15]. Women were asked to remain recumbent for one hour
following delivery of the baby, or for two hours if active bleeding
persisted. Fluids, urine, and feces were excluded from the blood-
loss measure by sweeping them to the side and into a receptacle.
CHOs in both groups were trained to monitor pulse, uterine tone,
and vaginal bleeding every 15 minutes for the first two hours
following delivery. Quantitative blood-loss measures and actions
taken to respond to that blood loss were utilized to estimate PPH,
the primary outcome, under three definitions:
1. PPH-1 is the traditional definition and includes blood loss
$500 mL one hour following delivery, or after two hours if
active bleeding persists at one hour. This traditional definition
is problematic in two ways in this trial design: some women in
both groups will be provided a treatment dose a) before
completing one hour postpartum or b) prior to reaching
500 mL blood loss, potentially manipulating the total blood
loss that might have occurred.
2. For this reason, PPH-2 includes PPH-1 plus any woman
receiving early treatment for PPH regardless of cumulative
blood loss. The denominator for PPH-1 and PPH-2 was all
enrolled women with a quantitative blood-loss measure.
3. Furthermore, some women may be referred to a higher level of
care for postpartum bleeding who are not included in either PPH-
1 or PPH-2. PPH-3 includes any woman without a quantitative
Oxytocin to Prevent Postpartum Hemorrhage in Ghana
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blood loss measure who was referred to higher care for postpartum
bleeding, in addition to all women included in PPH-1 and PPH-2.
The denominator for PPH-3 is all enrolled women.
Multiple definitions of PPH were therefore used to account for
the impact on cumulative blood loss of early treatment for
bleeding. In addition, we examined a variation of PPH-1, where
the cutoff was extended to 1000 mL to represent severe PPH,
given the common usage of this indicator.
Secondary outcomes assessed the safety and feasibility of
home-based PPH prevention. Safety outcomes were analyzed for
all enrolled women plus women who were referred to hospital
before delivery of the baby. Women referred before delivery were
included in the analysis of safety outcomes to account for the
possibility of oxytocin administration by the CHO before delivery
of the baby. Use of oxytocin before delivery of the baby was the
key secondary outcome regarding safety. Others included
maternal death, uterine rupture, stillbirth, early death of
newborns (one to three days after birth), difficulty in infant’s
breathing at birth, need for newborn resuscitation, and needle
stick injury. Fetal and infant outcomes were included as safety
indicators out of concern regarding inappropriate use of oxytocin
before delivery of the baby. Only basic indicators of feasibility
were examined here, including the percentage of women who call
for a CHO during labor, the percentage of deliveries for which
the CHO arrived prior to delivery, mean duration of time spent
(a) traveling to the household and (b) at the household, mean
number of household visits per CHO, and mean response rate
per CHO.
Data Collection
Data were collected at three time points: at initial enrollment,
during labor/delivery and immediate postpartum period, and
two to three days after delivery. Field workers conducted
interviews with women at the time of initial enrollment, which
included socio-demographic information, pregnancy history, and
use of health care. During the observation of women before and
after birth, CHOs documented birth outcomes and the timing
and completion of events and procedures using a structured
questionnaire. All questionnaires were translated and back-
translated from English to Bono/Twi and were pretested during
a one month preparation phase preceding commencement of
enrollment that permitted implementation of all field procedures
except the intervention. Clocks with timers were distributed to
CHOs to document timing of birth, injections, delivery of the
placenta, and blood-loss measurements. Two to three days
following delivery, field workers conducted separate follow-up
interviews with all enrolled women and their traditional birth
attendants (if one was present at birth) at their respective homes.
These interviews were conducted as an independent assessment
of the care provided to avoid relying on CHOs’ documentation of
their own behavior.
Sample Size
Given existing data on the crude birth rate (27/1,000), an
originally planned enrollment period of nine months, a mean
population size per CHO catchment area (4,250), and an assumed
proportion of deliveries at home and reachable by CHOs (28%),
Figure 1. The oxytocin in Uniject device. Source: PATH/Glenn Austin.
doi:10.1371/journal.pmed.1001524.g001
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we estimated a mean cluster size of 24. Without information on
PPH incidence, we estimated 10% based on a community-based
trial in India [10], and conservatively set a coefficient of variation
(k) = 0.35. Assuming a within-cluster loss to follow-up of 10%, we
estimated that 26 CHOs per group were required for 80% power
and 5% Type 1 two-sided error to detect a 50% reduction in PPH;
over a 9-month period, we estimated that this sample design would
yield 1,128 enrolled participants. In December 2011 (with 47% of
the initial sample size achieved), our Data Safety and Monitoring
Board met to examine trial progress. An external analyst assessed
effectiveness of the intervention and confidentially presented
results to the Board, which assessed them according to predeter-
mined stopping guidelines (nominal alpha 0.00305, calculated
using O’Brien-Fleming spending function). The trial was not
stopped for efficacy or any other reason. The Board recommended
increasing the sample size to account for 1) lower-than-expected
enrollment per cluster, 2) lower-than-expected overall rate of PPH,
and 3) imbalance in size of the oxytocin versus control clusters. In
response, we extended data collection to 19 months (the maximum
possible given available resources), estimating that this increase in
the recruitment period would bring total sample size to 1,651. In a
posthoc calculation, estimates of control-group incidence of PPH
and coefficient of variation were updated at this time using data
available at the interim analysis to re-estimate power to detect a
50% reduction in PPH-1 (67.6%) and PPH-2 (91.0%) given this
increased sample size.
Statistical Analysis
Analysis of primary and secondary outcomes was conducted
following an intent-to-treat approach. Maternal, household, and
socio-demographic variables; indicators of pregnancy history; and
a range of variables related to care provided during pregnancy and
prior to delivery were compared between the oxytocin and control
clusters. Indicators of oxytocin and control-group implementation
coverage and completeness were estimated for each group. Our
analyses of the primary and secondary outcomes were conducted
using individual-level data. The proportion of enrolled women
with each of the binary definitions of PPH and of the secondary
outcomes reflecting safety were estimated for each arm of the trial,
and the risk ratio of each outcome in oxytocin versus control
clusters was calculated using binomial regression with log link
function. We did not adjust for multiple testing of the varying
definitions of PPH. We additionally defined severe PPH as a
quantitative blood-loss measure $1,000 mL and followed an
identical analysis for between-group comparison. Mean blood loss
was estimated for each group, and the difference between groups
was estimated using linear regression. For all between-group
comparisons using individual-level data, we estimated standard
errors (and confidence intervals and p-values) by adjusting for
clustered allocation using general estimating equations [23]. We
additionally conducted a cluster-level analysis for the primary
outcome, calculating the probability of PPH in each cluster and
conducting a t-test with assumption of unequal variances to
estimate the absolute difference in PPH between the groups.
Stratified analyses included examination of PPH-1 and PPH-2 at
25%, 50%, 75%, and 100% of the cumulative sample size
enrolled, and parity.
Results
Enrollment was conducted between April 21, 2011 and
November 30, 2012, as planned following the interim analysis.
Figure 2 presents the trial profile. Community health officers
were assigned to work in oxytocin (28 CHOs) or control (26
CHOs) areas. Field workers identified 5,919 pregnant women at
seven months’ gestation or more, nearly all (99.9%) of whom gave
initial consent to participate in the study. The ratio of oxytocin to
control women among the initially consented was 0.68
(2,402:3514). Among the initially consented, 1,148 of 2,402
(47.8%) and 1,539 of 3,514 (43.8%) women in the oxytocin and
control groups, respectively, requested CHO presence during
labor. Among those who did not call for a CHO, 698 of 1,254
(55.7%) women in the oxytocin arm and 910 of 1,975 (46.1%)
controls chose a health facility delivery. Among those who called
for CHO presence at delivery, 689 of 1,148 (60.0%) women in
the oxytocin group and 897 of 1,539 (58.3%) controls had their
delivery observed by a CHO. The ratio of enrolled women in the
oxytocin versus control arm was 0.77 (689:897). The two
predominant reasons for non-enrollment in both groups were:
CHO did not arrive, and CHO referred the woman for facility-
based care before delivery. Seven and nine enrolled women in the
oxytocin and control arms, respectively, lacked a blood-loss
measure.
The randomization process achieved balance between oxytocin
and control clusters on a range of women’s characteristics
(Table 1) and on indicators of recruitment, enrollment, and
measurement procedures (Table 2). Two CHO behaviors differed
between oxytocin and control groups. Among CHOs called by
women prior to birth, oxytocin CHOs referred women to hospital
prior to delivery in 198 of 1,148 (17.3%) deliveries as compared
to 192 of 1,539 (12.5%) deliveries referred by control CHOs.
Likewise, in 58 of 689 (8.4%) enrolled oxytocin deliveries and 278
of 897 (31.1%) enrolled control deliveries, CHOs tied on the
drape after delivery of the baby and before delivery of the
placenta, as opposed to before delivery of the baby, per protocol.
The mean duration between birth and unfolding the drape,
which could potentially affect blood-loss measurement, confirms
a delay of one minute on average by control CHOs relative to
oxytocin CHOs (4.4 minutes [SD: 5.7] versus 3.4 minutes [SD:
5.4], respectively).
Primary outcome data were available for 682 women in the
oxytocin group and 888 women in the control group (Table 3).
The PPH-1 rate among women in the oxytocin group was 2.6%
(18 of 682) versus 5.5% (49 of 887) among controls (RR: 0.491;
95% CI: 0.274–0.882). The PPH-2 rate among women in the
oxytocin group was 3.8% (26 of 682) versus 10.8% (96 of 887)
among controls (RR: 0.338; 95% CI: 0.181–0.630). The PPH-3
rate among women in the oxytocin group was 4.1% (28 of 682)
versus 11.1% (99 of 888) among controls (RR: 0.361; 95% CI:
0.196–0.664). There were nine cases of severe PPH; all but one
occurred in the control group (RR= 0.147; 95% CI: 0.013–
1.70). Figure 3 presents a box plot illustrating the median, 25%,
and 75% quartiles for blood loss by arm of the trial; median
blood loss for those in the oxytocin group was 150 mL and
among the controls it was 200 mL. Mean blood loss was
185.5 mL and 229.2 mL for oxytocin and control deliveries,
respectively. Mean reduction in blood loss was 45.1 mL (95%
CI: 17.7–72.6). When PPH-1 was examined in a cluster-level
analysis, there was an absolute risk difference of 3.2% (95% CI:
0.3%–6.2%).
There was slight variation in the quarter-specific estimates of
PPH-1 and PPH-2, but no statistical evidence that these
variations represented any secular trend in incidence in either
the intervention or the control group (Figures 4 and 5).
Similarly, the impact of prophylactic oxytocin on PPH rates
did not vary across time period (p-value for time period
interactions ranged from 0.51 to 0.89). The reductions in PPH-3
incidence were larger among primiparous women (RR: 0.231;
Oxytocin to Prevent Postpartum Hemorrhage in Ghana
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Figure 2. CONSORT flow diagram.
doi:10.1371/journal.pmed.1001524.g002
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Table 1. Assessment of balance between the oxytocin and control groups achieved through the randomization process among
enrolled women.
Enrollment Indicators/Characteristics Oxytocin Control
Woman’s age (years) (m, SD) 27.5 (6.6) 26.9 (6.8)
Woman’s age group (n, %)
15–19 75 (10.9) 121 (13.5)
20–29 351 (50.9) 460 (51.3)
30–39 228 (33.1) 282 (31.4)
40–49 35 (5.1) 34 (3.8)
Woman’s education (n, %)
None 331 (48.0) 418 (46.6)
Some primary school 146 (21.2) 203 (22.6)
Middle/Continuation 195 (28.3) 264 (29.4)
Technical/Secondary/University 17 (2.5) 12 (1.3)
Ethnic group (n, %)
Akan 211 (30.6) 309 (34.4)
Dagarti/Frafra/Kusasi 146 (21.2) 143 (15.9)
Gonja/Dagomba/Mamprusi 99 (14.4) 190 (21.2)
Konkomba/Basare 84 (12.2) 127 (14.2)
Mo 52 (7.5) 37 (4.1)
Other ethnicities* 97 (14.1) 91 (10.1)
Marital status (n, %)
Married 446 (64.7) 503 (56.1)
Living together 168 (24.4) 331 (36.9)
Divorced/Separated/Widowed 14 (2.0) 10 (1.1)
Single/Unmarried 61 (8.9) 53 (5.9)
Religion (n, %)
Catholic 153 (22.2) 164 (18.3)
Protestant 159 (23.1) 137 (15.3)
Pentecostal 169 (24.5) 263 (29.3)
Muslim 165 (23.9) 264 (29.4)
Traditional/Other 43 (6.2) 69 (7.7)
Parity (live and stillbirth) (n, %)
No prior births 133 (19.3) 181 (20.2)
1 123 (17.9) 194 (21.6)
2 to 4 298 (43.3) 354 (39.5)
5 or more 135 (19.6) 168 (18.7)
Wealth score (0–10)** (m, SD) 3.6 (2.0) 3.8 (2.0)
Previous stillbirth (n, %)
No prior pregnancy 115 (16.7) 161 (17.9)
None 549 (79.7) 695 (77.5)
Yes 25 (3.6) 41 (4.6)
Previous early neonatal death (n, %)
No prior pregnancy 115 (16.7) 161 (17.9)
None 546 (79.2) 694 (77.4)
Yes 28 (4.1) 42 (4.7)
Prior delivery location (n, %)
No prior pregnancy 115 (16.9) 161 (18.2)
Hospital/Health center 146 (21.5) 174 (19.7)
Home/Other 419 (61.6) 550 (62.1)
Missing 9 12
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95% CI: 0.067–0.795) and women at parity five or higher (RR:
0.210; 95% CI: 0.054–0.821), compared to those with two to
four births (RR: 0.461; 95% CI: 0.246–0.867); results were
similar for PPH-1 and PPH-2, but in no case were the
interaction terms statistically significant (Tables S1 and S2).
Stillbirth, early neonatal death (death prior to follow-up
interview), difficulty breathing at birth, and need for infant
resuscitation occurred at similar frequency across the groups
(Table 4), and none of these showed a statistically significant
relationship with receipt of prophylactic oxytocin. There were no
cases of oxytocin use during labor, maternal death, uterine
rupture, or needle stick injury. There were no major adverse
events or unanticipated harmful events that required notification
of the institutional review boards.
Table 1. Cont.
Enrollment Indicators/Characteristics Oxytocin Control
Prior pregnancy antenatal care (ANC) (n, %)
No prior pregnancy 115 (16.9) 161 (18.2)
None 26 (3.8) 51 (5.8)




Singleton 669 (98.1) 879 (98.8)
Twins 13 (1.9) 11 (1.2)
Missing 7 7
Reported size of baby***
Smaller than normal 13 (1.9) 34 (3.9)
Normal 526 (78.7) 698 (79.4)
Larger than normal 129 (19.3) 147 (16.7)
Missing 21 18
Birth attendant
Traditional birth attendant 647 (94.9) 862 (97.0)
Family member 27 (4.0) 21 (2.4)
Study participant herself 8 (1.2) 2 (0.2)
Other 0 (0.0) 4 (0.4)
Missing 7 8
Receipt of traditional preparation to speed labor (n, %)
Yes 59 (8.7) 75 (8.4)
No 622 (91.3) 817 (91.6)
Missing 8 5
Receipt of traditional preparation to stop postpartum bleeding (n, %)
Yes 2 (0.3) 3 (0.3)
No 667 (99.7) 866 (99.7)
Missing 20 28
Receipt of pharmaceutical drug (from any provider) to speed labor (n, %)
Yes 0 (0.0) 0 (0.0)
No 680 (100.0) 887 (100.0)
Missing 9 10
Receipt of pharmaceutical drug to stop bleeding postpartum (provided by someone other than the
community health officer [CHO]) (n, %)
Yes 0 (0.0) 3 (0.4)
No 618 (100.0) 781 (99.6)
Missing 71 113
Report of duration of labor, in hours (m, SD) 3.9 (3.1) 3.8 (4.1)
*Includes: Bimoba/Chokosi, Fulani, Ga/Adangbe/Ewe, Sisala/Wala, Zambraba, Banda/Pantra, and other (non-specified).
**Score based on unweighted sum of 10 household assets (electricity, radio, cooker, refrigerator, television, sewing machine, cell phone, cement floor, cement walls,
non-thatch roof).
***Reported among singleton births only.
doi:10.1371/journal.pmed.1001524.t001
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Regarding intervention feasibility and success in service
delivery, among initially consented women in the oxytocin and
control groups 47.8% (1,148 of 2,402) and 43.8% (1,539 of 3,514),
respectively, requested CHO presence at birth. The rate of health
facility–based births in the CHO catchment areas remained stable
over the 19-month period ranging from 34%–35% (n= 5919
deliveries). Among women requesting CHO presence at birth (in
the oxytocin group n= 1,148 and in the control group n= 1,539),
CHOs successfully arrived before delivery for 893 (77.8%) of
oxytocin deliveries and 1,089 (70.8%) of control deliveries.
Reasons for CHO non-compliance generally reflected scheduling
or infrastructure issues (e.g., out of town, no cell phone coverage,
phone battery dead, concurrent CHO outreach activities). On
average, CHOs in the oxytocin and control groups responded to
Table 2. Assessment of balance in recruitment, enrollment, measurement, coverage of the intervention, and early postpartum
hemorrhage (PPH) treatment between groups.
Recruitment/Enrollment Indicator Oxytocin Control
Among all women approached (n, %)
Refused initial consent 2 (0.1) 1 (0.0)
Agreed to initial consent 2,402 (99.9) 3,514 (100.0)
Among all participating pregnancies
Called community health officer (CHO) or field worker (FW) 1,146 (47.7) 539 (43.8)
Did not call 1,256 (52.3) 1,975 (56.2)
Among those that called CHO or FW
Enrolled 689 (60.3) 897 (58.3)
Not enrolled - CHO late or did not arrive 255 (22.3) 450 (29.2)
Not enrolled - referred before delivery 198 (17.3) 192 (12.5)
Measurement Indicators
Status of placing the drape
Before delivery 618 (90.0) 593 (66.3)
After delivery, before placenta 58 (8.4) 278 (31.1)
After delivery of placenta 4 (0.6) 12 (1.3)
Not tied/missing 7 (1.0) 11 (1.2)
Time between delivery and unfolding of the drape (minutes) (m, SD) 3.4 (5.4) 4.4 (5.7)
Portion of first hour spent lying on back after drape applied
60 minutes 649 (96.4) 855 (98.2)
50–59 minutes 11 (1.6) 9 (1.0)
40–49 minutes 10 (1.5) 4 (0.5)
,40 minutes 3 (0.4) 3 (0.3)
Quantitative blood measurement available (i.e., is PPH-1 defined)?
No 7 (1.0) 10 (1.1)
Yes 682 (99.0) 887 (98.9)
Intervention Characteristics
Received prophylactic injection
No 12 (1.7) 896 (99.9)
Yes 677 (98.3) 1 (0.1)
Timing of prophylactic injection
Not received 12 (1.7) 896 (99.9)
After delivery, before placenta 667 (96.9) 1 (0.1)
After delivery, after placenta 9 (1.3) 0 (0.0)
Location of prophylactic injection
Not received 12 (1.7) 896 (99.9)
Thigh 677 (98.3) 1 (0.1)
Time to prophylactic intervention (minutes) (m, SD) 1.79 (3.4) 21.00 (0.0)
Early PPH Treatment
Among all women with PPH-3 (n, %)
Received early treatment of oxytocin (10 IU) 24 (85.7) 90 (90.9)
Did not receive early PPH treatment 4 (14.3) 9 (9.1)
doi:10.1371/journal.pmed.1001524.t002
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1.7 and 2.2 calls per month, respectively. However, across CHOs
the means per month in the oxytocin (n = 28 CHOs) and control
groups (n = 26 CHOs) varied from 0.1–5.0 and 0–6.6, respectively.
Likewise, the mean CHO response rate, defined per CHO as the
percent of CHO household visits among all requests for service,
was 69.9% (varying from 33%–100%) in the oxytocin group
(n = 28 CHOs) and 69.7% (varying from 0%–100%) in the control
group (n= 26 CHOs).
All cases of PPH should have received early treatment and
been transported for higher level care; 24 of 28 (85.7%) of all
PPH-3 cases in the oxytocin group and 90 of 99 (90.9%) in the
control group received early treatment. However, only 35.7%
(10 of 28) and 18.2% (18 of 99) women with PPH-3 in the
oxytocin and control groups, respectively, were transported to
hospital; reasons for non-compliance included bleeding stopped
and/or the woman refused. There were no reported cases of
CHOs using a Uniject device with a time/temperature indicator
indicating ‘‘discard’’ in either group. In 1 and 2 oxytocin and
control deliveries, respectively, the CHO did not provide an
injection because the time/temperature indicator indicated
‘‘discard’’.
Discussion
This community-based, cluster-randomized trial of prophylactic
oxytocin (10 IU) administered via Uniject by peripheral health
care providers without midwifery skills showed statistically
significant reductions of 51% in the risk of PPH for blood loss
$500 mL and 66% for blood loss $500 mL or with gushing and
large blood clots. Results for severe PPH ($1,000 mL) were not
statistically significant. All secondary outcomes suggested the
intervention was safe.
The magnitude of protective effect for blood loss $500 mL in
this trial is similar to results shown for community-based
prophylactic misoprostol (600 mcg) versus placebo in rural India
(47% reduction in PPH) [10] and to a meta-analysis of health
facility–based prophylactic use of intramuscular and intravenous
oxytocin versus no uterotonics in high-income countries (50%
reduction in PPH defined as $500 mL blood loss; 95% CI: 0?43–
0?59) [9]. PPH reduction in this study was greater than trial results
shown for prophylactic misoprostol (600 mcg) versus placebo in
rural Pakistan (24% reduction in PPH) and in Guinea Bissau (11%
non-significant reduction in PPH) [11,12]. Mean blood loss among
Figure 3. Median blood loss by study arm of the trial.
doi:10.1371/journal.pmed.1001524.g003
Table 3. Primary outcome measures, by group.
Control Oxytocin
Outcome N Cases Percentage (%) N Cases Percentage (%) Relative Risk (95% CI) p-value
PPH-1 887 49 5.5 682 18 2.6 0.491 (0.274–0.882) 0.02
PPH-2 887 96 10.8 682 26 3.8 0.338 (0.181–0.630) 0.001
PPH-3 888 99 11.1 682 28 4.1 0.361 (0.196–0.664) 0.001
Severe PPH 887 8 0.9 682 1 0.1 1.000 (0.013–1.700) 0.12
Note: The intra-class correlation coefficients for PPH-1, PPH-2, and PPH-3 were 0.012, 0.051, and 0.050, respectively.
doi:10.1371/journal.pmed.1001524.t003
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both oxytocin and control women in this trial was lower than that
reported in these community-based misoprostol trials. Our results
show mean blood loss of 185.5 mL and 229.2 mL among oxytocin
and control deliveries, respectively, as compared to results from
India (214.3 mL versus 262.3 mL), Pakistan (337 mL versus
366 mL), and Guinea Bissau (443 mL versus 496 mL) [11–13].
Lower blood loss in this trial is expected, as early treatment of PPH
with an additional injection of oxytocin (10 IU) in both our trial
arms likely reduced ultimate blood loss among all PPH cases.
Several limitations of this study warrant discussion. The ratios of
numbers of women in oxytocin and control arms of the trial range
from 0.68 at the identification of eligible pregnancies to 0.77 at
enrollment. Prior to randomization, CHO catchment areas were
stratified by distance to emergency obstetric care, but not by
Figure 4. Trend in PPH-1 by study arm of trial.
doi:10.1371/journal.pmed.1001524.g004
Figure 5. Trend in PPH-2 by study arm of trial.
doi:10.1371/journal.pmed.1001524.g005
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population size, as these data were only available for Kintampo
North and South. In these two districts, the ratio of population in
the oxytocin versus control catchment areas is 0.88, explaining
some, but not all, of the imbalance. As shown in Table 2, fertility
between study arms is similar. There was no evidence that field
workers in the oxytocin arm systematically missed identifying more
pregnant women than in the control arm. However, if they did, it
is unlikely that these women would have substantially different
characteristics than the homogenous group that provided initial
consent for the study (and which represented 99% of all identified
pregnancies in both groups).
Two CHO behaviors differed by arm of the trial. First, control
CHOs initiated blood-loss measurement (i.e., unfolded the drape)
on average one minute later than oxytocin CHOs following
delivery, possibly leading to an underestimate of blood loss in the
control group. However, if delayed unfolding of the drape by
control CHOs reduced blood loss measures, it would underesti-
mate impact of oxytocin on outcomes. Second, CHOs in the
oxytocin group referred women prior to delivery more frequently
(17.3%) than control CHOs (12.5%), possibly indicating that the
analyzable sample in the oxytocin group excluded a larger pool of
women having a difficult delivery and thus potentially at higher
risk of PPH. Data extracted from hospital records for referred
women did not, however, indicate a higher risk (6 PPH cases
among 198 referred women in the oxytocin group= 3.0%).
In an un-blinded study, differential measurement errors across
arms of the trial are possible and thus, lack of blinding constitutes a
study limitation. However, in this study the intervention was
provided by CHOs who were not birth attendants. They were not
responsible for managing the births nor were they responsible for
the birth outcome, two issues which we believe would decrease the
chances that they influenced the study outcome. The CHO’s job
was to respond to the call, to give (or not give) the injection and
measure blood. They had no previous experience with birth, or
visual blood loss estimation and possible associations with bad
maternal outcomes.
This trial provides evidence that administration of intramuscu-
lar prophylactic oxytocin in Uniject by peripheral health care
providers without midwifery skills can effectively decrease the risk
of PPH at home births under research conditions. Furthermore,
none of the secondary outcomes reflecting safety suggested that
this intervention was unsafe. Across trial arms, service was
successfully provided to three-quarters of all calls requesting
CHO assistance. However, CHO compliance varied widely, and
was likely due to CHOs working alone in their catchment area per
trial protocol; that is, they were on call 24 hours per day for 19
months. In a scaled-up program, additional staffing or the ability
to refer calls to a neighboring CHO would be required to increase
and sustain CHO compliance. There is no evidence that the
intervention decreased health facility–based births. However, 17%
of pregnant women (n= 5919) chose to deliver at home without a
CHO and research is needed to understand the barriers to
reaching these women. Another concern was the frequent lack of
compliance with free referral to hospital for PPH cases. Refusal of
referrals was unexpected and underscores the importance of
providing community-based early treatment to women reluctant to
seek care outside the home.
Cost is an important component of intervention feasibility.
Oxytocin in Uniject is currently commercially available only in a
few Latin American countries and thus its eventual market-driven
cost is unknown. The United Nations Commission on Life-Saving
Commodities for Women and Children includes oxytocin among
13 medicines unavailable to women due to issues such as cost or
supply because they are not subsidized by global bulk purchase
agreements or advance market commitments. The Commission
has developed specific recommendations to address these issues as
well as to promote oxytocin in a Uniject-type device [24]. It is
anticipated that oxytocin in Uniject will cost US$1.00 or less, and
potentially substantially less once sustained demand is established.
The oxytocin in Unijects used in this study, were purchased on a
non-commercial basis at a cost of $1.40 per dose. A commercial
price for the product, should sustainable demand emerge, could be
lower as economies of scale play a significant role in the cost of
producing pharmaceutical products.
These results also raise additional questions. For example, if
oxytocin in Uniject is not an option, could providers entrusted to
vaccinate children and provide other injections use a traditional
syringe and ampoule for oxytocin administration? The skills
required are the same as are issues regarding needle disposal. As a
cost-saving measure, could a time/temperature indicator be
placed on a flat of oxytocin ampoules (versus individual ampoules),
since ampoules within a flat are generally exposed to the same
environmental conditions? This issue is mentioned in the UN
Commission on Life-Saving Commodities for Women and
Children and will likely be determined by the willingness of
pharmaceutical companies to allow it. Regarding the duration that
oxytocin can remain out of the cold chain in hot climates,
additional analyses from this trial are currently underway to assess
the number of days that oxytocin can remain out of the cold chain
under field conditions in central Ghana prior to indication by the
time/temperature indicator that the device should be discarded.
Such information will serve health care planners in determining
the required resupply schedule and the feasibility of this schedule
locally. Could a lay provider safely and effectively use oxytocin in
Uniject? (A randomized trial assessing use of oxytocin in Uniject
by traditional birth attendants to prevent PPH is underway in
Senegal now; clinicaltrials.gov: NCT01713153.) Is the BRASSS-V
calibrated plastic drape used here necessary or could a simplified
drape that indicates only when treatment and referral are needed
(versus a quantitative blood loss measure), or other PPH detection
Table 4. Secondary safety outcome measures, by group.
Control Oxytocin
Outcome N Cases Percentage (%) N Cases Percentage (%) Relative Risk (95% CI) p-value
Stillbirth 1,095 18 1.6 911 19 2.1 1.309 (0.851–2.016) 0.22
Early infant death (within 0–3 days) 1,077 7 0.6 892 6 0.7 1.000 (0.320–3.127) 1.00
Infant did not breathe at birth 891 48 5.4 684 45 6.6 1.129 (0.575–2.216) 0.72
Infant resuscitation* 891 26 2.9 684 11 1.6 0.632 (0.199–2.009) 0.44
*Defined as: clearing of infant airways, ventilation, cardiac massage.
doi:10.1371/journal.pmed.1001524.t004
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pads suffice? This choice will be determined by the objectives of
local health planners and the ability to easily obtain or import
supplies. In Ghana, local manufacture of the blood loss
measurement drape is considered a priority for scaled-up use.
While the move towards use of skilled birth attendants is
gathering global momentum, poverty and inequity—particularly
in selected areas in countries—will remain issues for the
foreseeable future. Prophylactic use of uterotonics to prevent
PPH, the biggest killer of women during childbirth, is a key
intervention and use of oxytocin as the drug of choice should be
considered where its use is feasible. It is unhelpful to pose this issue
as oxytocin versus misoprostol. The more appropriate question is:
Where and under what circumstances can each of these proven
effective drugs be used? Ultimately, decisions regarding the
balance of advantages and disadvantages of using oxytocin or
misoprostol for PPH prevention at home births will depend on
local conditions, human resources, infrastructure, and national
policies.
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Editors’ Summary
Background. Many women in low-and middle-income
countries die unnecessarily during childbirth, even though
the solutions to prevent or manage complications are well
known. Maternal death rates are highest amongst poor
women living in remote areas, as they are least likely to have
access to adequate health care. One of the United Nation’s
Millennium Development Goals is to reduce maternal death
rates by three-quarters by 2015. Between 1990 and 2010,
these rates were nearly halved. So there is still some way to
go to meet the target.
One of the major causes of maternal death is excessive
bleeding after birth, known as postpartum hemorrhage
(PPH). The highest rates of PPH are found in Africa (28% of
births), with an overall global rate of 11%. PPH can be caused
by the uterus not contracting after the baby is born, damage
to tissues and blood vessels, retention of the placenta, and
problems with blood-clotting.
PPH can be prevented by an injection of oxytocin (a
hormone) or with tablets of the drug misoprostol immedi-
ately after birth. Other drugs exist but are used much less
frequently in low-income countries. If the mother does bleed
excessively, then these interventions can also be used to
treat PPH in the hours following birth. These drugs cause the
uterus to contract. Continued severe bleeding requires
emergency treatment in hospital. The World Health Organi-
zation (WHO) recommends that in situations where women
give birth without the assistance of a trained midwife,
priority should be given to preventing PPH because access
to emergency services may be limited.
Why Was This Study Done? Of the two most common
options for preventing PPH, oxytocin is generally the
preferred choice. It has the advantage of having no side
effects, whereas misoprostol can cause fever and shivering. A
repeat injection of oxytocin can also be given if the mother
continues to bleed excessively, whereas a dose of misopros-
tol after birth should only be given once. A major concern
about both drugs is that the timing of administration must
be precise. Giving a drug that causes the uterus to contract
before birth can be harmful to both mother and baby. A
disadvantage of oxytocin is that it requires someone trained
and authorized to give an injection. For this reason, oxytocin
has so far been generally limited to hospitals and clinics,
where it can be administered by medically trained profes-
sionals. Another disadvantage is that oxytocin is weakened
by heat, which means its storage and use may be impractical
in hot countries.
The main aim of this study was therefore to find out whether
health workers without midwifery skills are able to admin-
ister oxytocin safely when attending home births in poor,
rural communities.
What Did the Researchers Do and Find? The researchers
carried out a cluster-randomized controlled trial in four rural
districts in Ghana, working with community health officers
(CHOs). CHOs are trained for two years in giving childhood
immunizations and antenatal and postnatal care, but are not
trained midwives. 54 CHOs were randomized to one of two
groups. The CHOs in the first group gave a preventative
oxytocin injection to the mother at every birth they
attended. The oxytocin was administered using a pre-filled,
disposable device called Uniject that is easier and quicker to
use than a syringe and needle. The packaging also included a
heat-sensitive label that indicated whether the oxytocin still
met the manufacturer’s criteria for an acceptably potent
drug. CHOs in the second group acted as controls, and did
not give any oxytocin injections to prevent PPH. The women
seen by each CHO formed a cluster. Comparisons were made
across the clusters of women that either received or did not
receive the preventative intervention.
The researchers found that the women who were given a
preventative oxytocin injection lost less blood after birth
than the women who did not receive a preventative
injection. There were also fewer cases of PPH amongst the
women who received oxytocin for PPH prevention. 2.6% of
the women who received a preventative oxytocin injection
experienced PPH, compared to 5.5% of the controls.
Therefore the risk of PPH was approximately halved. There
were no cases of oxytocin use before delivery of the baby
and no difference in the frequency of other birth complica-
tions between women in the intervention and control
groups.
What Do These Findings Mean? These findings show
that under the trial conditions, CHOs can safely administer
oxytocin injections when attending home births in poor,
rural settings. This intervention also proved practical to use
in the Uniject format.
The study therefore suggests that oxytocin should be
considered for use in regions where maternal deaths from
PPH are still unacceptably high. There are also several
noteworthy limitations, such as unblinding and the imbal-
ance between participant groups. The researchers empha-
sized that their findings do not mean that oxytocin is always
a better choice than misoprostol for home births. Many
factors will influence which intervention is the most feasible,
such as the local availability of sufficiently skilled health
professionals, the relative cost and availability of the two
drugs, as well as ease of access to emergency health services.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001524.
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